biote Corp.

NasdaqGM BTMD

biote Corp. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD 38.91 M

biote Corp. Operating Income is USD 38.91 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 27.78% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

biote Corp. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 30.45 M, a 149.04% change year over year.
biote Corp. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -62.10 M, a -260.61% change year over year.
biote Corp. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 38.66 M.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: BTMD

biote Corp.

CEO	Ms. Teresa S. Weber
IPO Date	April 28, 2021
Location	United States
Headquarters	1875 West Walnut Hill Lane
Employees	194
Sector	Health Care
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Key trends

Past 5 years